Rationale of Statin Therapy in Septic Patients

被引:16
作者
Piechota, Mariusz [1 ]
Barylski, Marcin [2 ]
Hannam, Simon [3 ]
Piechota-Urbanska, Magdalena [4 ]
Banach, Maciej [5 ]
机构
[1] Mil Med Acad Univ Hosp Lodz, Dept Anesthesiol & Intens Therapy, PL-90647 Lodz, Poland
[2] Mil Med Acad Univ Hosp Lodz, Dept Internal Dis & Cardiol Rehabil, PL-90647 Lodz, Poland
[3] Kings Coll London, Dept Child Hlth, Sch Med, London WC2R 2LS, England
[4] Med Univ Lodz, Dept Appl Pharm, Lodz, Poland
[5] Med Univ Lodz, Dept Hypertens, Lodz, Poland
关键词
Bacteremia; infection; management; sepsis; statins; C-REACTIVE PROTEIN; NITRIC-OXIDE SYNTHASE; SEVERE SEPSIS; REDUCTASE INHIBITOR; MORTALITY; PRAVASTATIN; INFECTION; SHOCK; ATORVASTATIN; INFLAMMATION;
D O I
10.2174/1570161111311050018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Statins are well-established and effective drugs in the treatment of hyperlipidemias. However the effects of statins extend beyond lipid-lowering. The pleiotropic effects of statins have been shown to modify inflammatory cell signaling of the immune response to infection. Statins have emerged as potential immunomodulatory and antioxidant agents that might impact on sepsis outcomes. It was postulated that statins may be candidates for the treatment of sepsis. Recent animal and human data suggest that statin therapy might be beneficial in patients before the onset of sepsis or in its initial period, but should be used with care when patients are diagnosed with severe sepsis or septic shock. Some analyses also provide evidence for statins as an adjuvant therapy in sepsis. Because of the divergent results of studies, the potential benefit needs to be validated in randomized, controlled trials. In this review, we describe current evidence on the use of statins in the prevention and treatment of sepsis.
引用
收藏
页码:795 / 800
页数:6
相关论文
共 72 条
[1]  
Al Harbi Shmeylan A, 2011, BMC Clin Pharmacol, V11, P12, DOI 10.1186/1472-6904-11-12
[2]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[3]   Prior statin therapy is associated with a decreased rate of severe sepsis [J].
Almog, Y ;
Shefer, A ;
Novack, V ;
Maimon, N ;
Barski, L ;
Eizinger, M ;
Friger, M ;
Zeller, L ;
Danon, A .
CIRCULATION, 2004, 110 (07) :880-885
[4]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[5]  
Araujo-Filho Irami, 2010, Rev Col Bras Cir, V37, P39
[6]   Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model [J].
Aydin, Unal ;
Ugurlucan, Murat ;
Gungor, Funda ;
Ziyade, Sedat ;
Inan, Bekir ;
Banach, Maciej ;
Kalko, Yusuf ;
Yasar, Tahsin .
ANGIOLOGY, 2009, 60 (03) :370-377
[7]  
Banach M, 2009, MED SCI MONITOR, V15, pMS1
[8]   Adverse Effects of Statins - Mechanisms and Consequences [J].
Beltowski, Jerzy ;
Wojcicka, Grazyna ;
Jamroz-Wisniewska, Anna .
CURRENT DRUG SAFETY, 2009, 4 (03) :209-228
[9]   Anti-inflammatory and immunomodulatory effects of statins [J].
Blanco-Colio, LM ;
Tuñón, J ;
Martín-Ventura, JL ;
Egido, J .
KIDNEY INTERNATIONAL, 2003, 63 (01) :12-23
[10]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655